Clene Inc (CLNN)

$0.333

-0.02

(-4.64%)

Market is closed - opens 7 PM, 23 Apr 2024

Insights on Clene Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 108.0K → 170.0K (in $), with an average increase of 36.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -2.41M → -10.17M (in $), with an average decrease of 320.7% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 42.1% return, outperforming this stock by 106.1%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 231.4% return, outperforming this stock by 327.7%

Performance

  • $0.32
    $0.34
    $0.33
    downward going graph

    2.33%

    Downside

    Day's Volatility :5.54%

    Upside

    3.28%

    downward going graph
  • $0.25
    $1.09
    $0.33
    downward going graph

    24.24%

    Downside

    52 Weeks Volatility :77.06%

    Upside

    69.72%

    downward going graph

Returns

PeriodClene IncSector (Health Care)Index (Russel 2000)
3 Months
-28.75%
-0.7%
0.0%
6 Months
-30.62%
9.2%
0.0%
1 Year
-66.02%
3.5%
-1.3%
3 Years
-96.48%
12.3%
-22.1%

Highlights

Market Capitalization
44.8M
Book Value
$0.1
Earnings Per Share (EPS)
-0.47
Wall Street Target Price
5.0
Profit Margin
0.0%
Operating Margin TTM
-5841.18%
Return On Assets TTM
-52.33%
Return On Equity TTM
-595.47%
Revenue TTM
654.0K
Revenue Per Share TTM
0.01
Quarterly Revenue Growth YOY
-27.400000000000002%
Gross Profit TTM
447.0K
EBITDA
-38.8M
Diluted Eps TTM
-0.47
Quarterly Earnings Growth YOY
0.61
EPS Estimate Current Year
-0.3
EPS Estimate Next Year
-0.28
EPS Estimate Current Quarter
-0.07
EPS Estimate Next Quarter
-0.08

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Clene Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
12
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1401.5%

Current $0.33
Target $5.00

Technicals Summary

Sell

Neutral

Buy

Clene Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Clene Inc
Clene Inc
-22.56%
-30.62%
-66.02%
-96.48%
-96.3%
Moderna, Inc.
Moderna, Inc.
-3.81%
28.95%
-26.59%
-39.67%
329.16%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.28%
12.73%
12.52%
82.86%
168.48%
Novo Nordisk A/s
Novo Nordisk A/s
-4.7%
26.35%
43.96%
230.98%
410.23%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.87%
7.24%
20.15%
82.55%
128.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Clene Inc
Clene Inc
4.14
NA
NA
-0.3
-5.95
-0.52
NA
0.1
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.72
25.72
1.46
45.22
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.33
28.33
0.53
16.77
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Clene Inc
Clene Inc
Buy
$42.4M
-96.3%
4.14
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$38.8B
329.16%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
168.48%
25.72
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$550.4B
410.23%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.7B
128.04%
28.33
36.68%

Company Information

clene has a new vision for a pharmaceutical future using therapeutic elements in clean, new nanoforms. our patented clean-surface nanosuspension™ (csn) technology produces clean-surface nanocrystals at commercially viable rates. by coupling high-purity metallic donor materials with high-purity water, csn unlocks the potential of therapeutic nanoparticles and represents a clean break from the standard paradigm of small-molecule drugs and large-molecule biologics.

Organization
Clene Inc
Employees
82
CEO
Mr. Robert Etherington MBA
Industry
Healthcare

FAQs